A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

• Status: Completed
• Trial end date: 2018-07-06
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of subcutaneous (SC) risankizumab and oral FUMADERM provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and candidates for systemic therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie
• Treatments: Dimethyl Fumarate

Criteria

Inclusion Criteria:

• Have a diagnosis of chronic plaque psoriasis for at least 6 months before the first administration of study drug. Duration since diagnosis may be reported by the participant

• Participant has stable moderate to severe plaque psoriasis (body surface area [BSA] >10, Psoriasis Area and Severity Index [PASI] >10, and Dermatology Quality of Life Index [DLQI] >10) with or without psoriatic arthritis at Baseline

• Must be naïve to and candidate for systemic therapy, as assessed by the investigator

• Participant has an inadequate response, intolerance or contraindication to topical psoriasis treatment

Exclusion Criteria:

• Participants with non-plaque forms of psoriasis

• Participant has previously received systemic therapy for psoriasis, whether biologic or non-biologic or photochemotherapy

• Active systemic infection during the last 2 weeks (exception: common cold) prior to screening.

• Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix

• Participant has any condition or contraindication to Fumaderm that would preclude the patient's participation in the present study